Russian CRO acquires clinical research company in Argentina
This article was originally published in Scrip
The St Petersburg-based contract drug development company PSI has completed the acquisition of Thywill, a CRO headquartered in Buenos Aires, Argentina. Thywill specialises in clinical trials management across Latin America, and PSI hopes to benefit from this experience and expand its operations in Argentina, Peru, Ecuador, Uruguay, Colombia, Chile and Mexico. In addition to Russia and other ex-Soviet republics, PSI operates across Europe, and in North and South Americas. It employs more than 200 people in 22 countries who have experience in multinational regulatory issues relating to clinical research. In the 15 years passed since its establishment, the company completed more than 300 studies in all major therapeutic areas and more than 400 sponsor audits.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.